Visio Mobile Diagnostics Rolls Out CompuMed’s eHealth Technology to Markets Across Ohio

CompuMed, Inc. (OTCBB: CMPD) (http://www.compumed.net), a telemedicine and medical informatics company, reported its CardioGram® and OsteoGram® systems have been incorporated as core components of Visio Mobile Diagnostics’ suite of telemedicine and digital x-ray-based healthcare services.

Visio Mobile Diagnostics is Ohio’s largest provider of mobile x-ray and cardiac testing services, serving a wide array of regional and state government entities, leading corporations, healthcare organizations and professional sports teams. Visio has begun to rollout CompuMed’s digital telemedicine technology to hospitals, occupational and home health clients, as well as long-term care facilities in mobile and rural markets across Ohio.

Visio’s mobile services bring the diagnostic testing center directly to the patient. Services are scheduled at times that are convenient for the patient and can be provided virtually anywhere, including at home or work, or in long-term care facilities or the local physician’s office.

"Our CardioGram and OsteoGram technologies represent our leading eHealth initiatives, and they are revolutionizing the capabilities of mobile health care delivery,” said Maurizio Vecchione, president and CEO of CompuMed. "These advanced technologies bring the highest quality medical services to an increasingly wide array of patients in a practical and affordable way. We look forward to working closely with Visio Mobile Diagnostics, one of the nation’s premier innovators and providers of state-of-the-art mobile health care services.”

According to Doug Cook, CEO of Visio Mobile Diagnostics, "Our clients and staff are very impressed with the CardioGram and OsteoGram systems, which we have been able to rapidly implement in a demanding healthcare environment. We see this as a major game changer for us, helping us to solidify our position as Ohio’s premier provider of mobile medical testing services.”

This announcement follows CompuMed’s recently initiated campaign to reach underserved markets for cardiac care, which include geriatric, pediatric and rural healthcare. CompuMed plans to reach these markets by building upon its existing network of hundreds of CardioGram sites nationwide, each accessing advanced cardiovascular diagnostic services through Compumed’s telemedicine infrastructure.

CompuMed has launched a series of initiatives designed to deliver its telecardiology services via industry partners, like Visio, that already provide healthcare services to underserved markets. "We believe the changed reimbursement posture towards telemedicine allows us to offer these services to patients without creating new costs for our partners in these markets,” said Vecchione.

CompuMed’s long-standing status as a leader in the remote interpretation of electrocardiograms (ECGs) puts it ahead of the game in the emerging market for telemedicine, which is expected to nearly triple over the next three years, topping $1.6 billion according to Datamonitor.

CompuMed’s CardioGram – How it Works

CompuMed’s CardioGram is a portable device supported by proprietary work-flow software, with unique features designed to appeal to the cost-saving trends in eHealth, and makes performing a 12-lead ECG easier and more cost-efficient.

After patient preparation, the ECG is acquired with the push of a button. The ECG data is digitally transmitted via any phone or Internet connection to the company’s computer laboratory for instant analysis. ECG data is interpreted by sophisticated computer algorithm, and interpretations are available in near real-time at the CardioGram device. The data and interpretation can then be transferred to an electronic medical record (EMR) via CompuMed’s proprietary EMR software solution.

CompuMed’s EMR software also allows the company’s laboratory to process ECGs for any customer from any location, regardless of the brand of ECG machine used. However, the most unique and life-saving feature of the CardioGram is the device’s over-read capabilities or "The Doctor Inside™,” which immediately engages one of CompuMed’s on-call cardiologists to over-read the computerized interpretation. Cardiologist-generated interpretations can be made available to attending physicians at the point-of-care, providing expert interpretations in those situations where the data is ambiguous or difficult to interpret. The Doctor Inside is a key element of CompuMed’s unique approach to telemedicine and telecardiology.

About Visio Mobile Diagnostics

Visio Mobile Diagnostics offers specialized X-ray and cardiology procedures to healthcare agencies throughout Ohio. By embracing the new CR digital ‘filmless’ technology, as well as the World Wide Web, Visio is able to provide X-ray images and reports with unprecedented speed and accuracy. X-rays are processed right at your location allowing immediate access to images. Visit Visio Mobile Diagnostics on-line at www.visio-inc.com.

About CompuMed

CompuMed, Inc. (OTCBB: CMPD) develops and markets products and services that combine advanced imaging with medical informatics. Its focus is on analysis and remote monitoring for patients with cardiovascular and musculoskeletal diseases. The company has specialized expertise and intellectual property in telemonitoring imaging and analysis designed to improve healthcare provider workflow and patient care while reducing costs. CompuMed is headquartered in Los Angeles and distributes its products worldwide both directly and through OEM partners. Visit CompuMed at www.compumed.net and follow at Twitter: @compumed.

Forward Looking Statements

Statements contained in this press release that are not historical facts, such as statements about prospective earnings, savings, revenue, operations, revenue and earnings growth, results of contracts and other financial results, are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All such forward-looking statements including statements concerning the Company's plans, objectives, expectations and intentions are based largely on management's expectations and are subject to and qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These statements are subject to uncertainties and risks including, without limitation, competitive factors, outsourcing trends in the pharmaceutical industry, product and service demand and acceptance, changes in technology, ability to raise capital, the availability of appropriate acquisition candidates and/or business partnerships, economic conditions, the impact of competition and pricing, capacity and supply constraints or difficulties, government regulation and other risks identified in the Company's filings with the Securities and Exchange Commission including its Annual Report on Form 10-KSB and Quarterly Reports on Form 10-QSB. All such forward-looking statements are expressly qualified by these cautionary statements. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect events, conditions or circumstances on which any such statement is based after the date hereof, except as required by law.